Archives: Publications

September 14, 2013

Safety and Efficacy of RNAi Therapy of RNAi Therapy for Transthyretin Amyloidosis

Coelho et al., NEJM. 2013 Sept13 (Epub doi: 10.1056/NEJMoa1208760 )

August 28, 2013

Positive Clinical Trial Results with ALN-TTR01 and ALN-TTR02 Published in the “New England Journal of Medicine”

We have published complete study results from Phase I trials with ALN-TTR01 and ALN-TTR02 in the New England Journal of Medicine. RNAi therapeutics targeting transthyretin (TTR) achieved rapid, dose-dependent, durable, and specific knockdown of TTR, the disease-causing protein in TTR-mediated amyloidosis (ATTR). The Phase I studies of ALN-TTR01 and ALN-TTR02 demonstrate key human proof of Read More

June 25, 2013

Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics

Maier et al., Mol Ther. 2013 Jun25 (Epub doi: 10.1038/mt.2013.124)

June 23, 2013

Efficiency of siRNA Delivery by Lipid Nanoparticles is Limited by Endocytic Recycling

Sahay et al., Nat Biotechnol. 2013 Jun23 (Epub doi:10.1038/nbt.2614)

June 23, 2013

Image-based Analysis of Lipid Nanoparticle–mediated siRNA Delivery, Intracellular Trafficking and Endosomal Escape

Gilleron et al., Nat Biotechnol. 2013 Jun23 (Epub doi:10.1038/nbt.2612)

June 19, 2013

ALN-CC5 Historical Press Releases

Below is a list of historical press releases related to our ALN-CC5 program for the treatment of Complement-Mediated Disease: 2014 2013:

April 25, 2013

Monocyte-Directed RNAi Targeting CCR2 Improves Infarct Healing in Atherosclerosis-Prone Mice

Majmudar et al., Circulation. 2013 Apr24 (Epub doi: 10.1161/CIRCULATIONAHA.112.000116)

January 30, 2013

Complete Study Results from our ALN-VSP Phase I Trial and Extension Study Published in “Cancer Discovery”

We have published complete study results from our Phase I clinical trial with ALN-VSP, an RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. Results from the study – the most comprehensive study of a systemically administered RNAi therapeutic to date – demonstrated proof of RNAi activity in man and evidence of anti-tumor activity, Read More

December 8, 2012

An RNAi Therapeutic Targeting Tmprss6 Decreases Iron Overload in Hfe-/- Mice and Ameliorates Anemia and Iron Overload in Murine β-thalassemia intermedia

Schmidt et al., Blood. 2013 Feb14 (Epub doi: 10.1182/blood-2012-09-453977 )

December 7, 2012

ALN-TMP Historical Press Releases

Below is a list of historical press releases related to our ALN-TMP for the Treatment of Beta-Thalassemia and Iron Overload Disorders: 2013 2012